Analyst Ratings for Fate Therapeutics
Portfolio Pulse from Benzinga Insights
Fate Therapeutics (NASDAQ:FATE) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 4 indifferent ratings. The average 12-month price target for the stock, according to 6 analysts, is $6.4, a decrease of 26.18% from the previous average of $8.67.
September 07, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Fate Therapeutics has received mixed analyst ratings, with an average 12-month price target of $6.4, down 26.18% from the previous average.
The mixed analyst ratings indicate uncertainty about the company's performance. The decrease in the average price target suggests that analysts have lowered their expectations for the stock, which could potentially impact its price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100